4 assets in Myxoid/Round Cell Liposarcoma

Therapeutic assets addressing Myxoid/Round Cell Liposarcoma, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Cyclophosphamide Myxoid/Round Cell Liposarcoma	Sotio Biotech Inc.	P1/2	CCC (54)
Fludarabine Myxoid/Round Cell Liposarcoma	Sotio Biotech Inc.	P1/2	CCC (54)
gpc3-car-t cells Myxoid/Round Cell Liposarcoma	Sotio Biotech Inc.	P1/2	CCC (48)
Autologous Genetically Modified Mage-A4ᶜ¹º³²T Cells Myxoid/Round Cell Liposarcoma	USWM CT, LLC	P1	CC (43)